SciClone Pharmaceuticals Inc
Jiting Yan has extensive work experience in business development and strategy roles. Starting in 2007, they worked as an Associate at Boston Consulting Group (BCG) before moving on to Business Research Limited, where they served as the Chief Representative in China and later as a BD Manager. In 2017, Yan joined Sihuan Pharmaceutical Holdings Group as a BD Director, and in 2019, they became an Associate Director - Strategy & BD at Fresenius Kabi. Currently, Yan holds the position of BD Director at SciClone Pharmaceuticals.
Jiting Yan holds a Master of Science (MS) degree in Applied Biotechnology from Uppsala University. Additionally, Jiting Yan was an Exchange student at Goethe University Frankfurt, where they studied Biology.
This person is not in any offices
SciClone Pharmaceuticals Inc
SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.